---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002065"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:55:40.331281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical extends loan maturity to 2029, provides preliminary Q4 net sales $21.3M-$22.3M

## Summary
- Amended loan with Innovatus: $8.0M principal, interest-only 30-36 months, maturity extended from Mar 2025 to Jan 2029.
- Issued warrant to Innovatus for 191,096 shares at $1.83 per share, exercisable through Jan 2029.
- Preliminary Q4 2023 net sales $21.3M-$22.3M (10-16% YoY growth); gross profit $1.6M-$2.6M; adj. EBITDA ($0.9M)-$0.1M.
- Full-year 2023 net sales projected $82.8M-$83.8M (14-15% growth); gross profit $7.4M-$8.4M; adj. EBITDA ($5.5M)-($4.5M).
- Cash and equivalents $11.0M at Dec 31, 2023, down slightly from $11.7M at Sep 30, 2023.

## SEC filing metadata
- accession: 0001104659-24-002065
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/tm242195d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002065
- JSON: https://secwatch.observer/filing/0001104659-24-002065.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002065.txt

## Key facts
- Debt Financings
  ROCKWELL MEDICAL, INC. amended credit facility of $8.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50% maturing fifth anniversary of the Effective Date.
  - Instrument: credit facility
  - Principal: $8.0 million
  - Counterparty: Innovatus Life Sciences Lending Fund I, LP
  - Rate: the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50%
  - Maturity: fifth anniversary of the Effective Date
  - Event: amendment
  source text: for the continuation of term loans initially borrowed on or after the Original Effective Date, in an aggregate outstanding principal amount as of the Effective Date of $8.0 million (the “Term Loans”). The Company will make interest-only payments on the Term Loans for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported three months ended December 31, 2023 results: revenue between $21.3 million and $22.3 million, net income ($2.2) to ($1.2). Guidance reaffirmed.
  - Period: three months ended December 31, 2023
  - Revenue: between $21.3 million and $22.3 million
  - Net income: ($2.2) to ($1.2)
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: 8, 2024. 1 Rockwell Medical Preliminary Fourth Quarter and Full-Year 2023 Projected Results Rockwell Medical projects net sales in the fourth quarter of 2023 to be between $21.3 million and $22.3 million, a 10% to 16% increase over net sales of $19.3 million for the same period in 2022; gross profit for the fourth quarter of 2023 to be between $1.6 million and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported twelve months ended December 31, 2023 results: revenue between $82.8 million and $83.8 million, net income ($9.1) to ($8.1). Guidance reaffirmed.
  - Period: twelve months ended December 31, 2023
  - Revenue: between $82.8 million and $83.8 million
  - Net income: ($9.1) to ($8.1)
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: in the fourth quarter of 2023. Rockwell Medical is narrowing its full-year 2023 guidance and projects net sales for the twelve months ended December 31, 2023 to be between $82.8 million and $83.8 million, a 14% to 15% increase over net sales of $72.8 million in 2022, and gross profit for the full-year 2023 to be between $7.4 million and $8.4 million, an 80% to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.